Similarly, apigenin targets the PI3K/Akt and integrin β1-FAK signaling pathways, disrupting tumor survival mechanisms and limiting growth, particularly in treatment-resistant cancers (Tripathi et al., 2024). This evidence concerns the gene AKT1 and cancer.